Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. It is a small molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.. Reference standards of Brigatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
stdClass Object ( [pname] => Brigatinib [catalogue_number] => PA 29 44000 [category_ids] => ,78,72,80,79, [chemical_name] => [weight] => 584.09 [form] => C29H39ClN7O2P [cas] => 1197953-54-0 [pslug] => 1197953-54-0-brigatinib-api-pa2944000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 29 44000
CAS :
Molecular Formula : C29H39ClN7O2P
Molecular Weight : 584.09
stdClass Object ( [pname] => 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl] [catalogue_number] => PA 29 0441000 [category_ids] => ,171,78,72,80,79, [chemical_name] => [weight] => 570.07 [form] => C28H37ClN7O2P [cas] => 1197958-75-0 [pslug] => 1197958-75-0-2-4-pyrimidinediamine-5-chloro-n4-2-dimethylphosphinyl-phenyl-n2-2-methoxy-4-4-1-piperazinyl-1-piperidinyl-phenyl-pa290441000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 29 0441000
Molecular Formula : C28H37ClN7O2P
Molecular Weight : 570.07
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
